Isoniazid and host immune system interactions: A proposal for a novel comprehensive mode of action

23Citations
Citations of this article
101Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The known mode of action of isoniazid (INH) is to inhibit bacterial cell wall synthesis following activation by the bacterial catalase–peroxidase enzyme KatG in Mycobacterium tuberculosis (Mtb). This simplistic model fails to explain (a) how isoniazid penetrates waxy granulomas with its very low lipophilicity, (b) how isoniazid kills latent Mtb lacking a typical cell wall, and (c) why isoniazid treatment time is remarkably long in contrast to most other antibiotics. To address these questions, a novel comprehensive mode of action of isoniazid has been proposed here. Briefly, isoniazid eradicates latent tuberculosis (TB) by prompting slow differentiation of pro-inflammatory monocytes and providing protection against reactive species-induced “self-necrosis” of phagocytes. In the case of active TB, different immune cells form INH-NAD+ adducts to inhibit Mtb's cell wall biosynthesis. This additionally suggests that the antibacterial properties of INH do not rely on KatG of Mtb. As such, isoniazid-resistant TB needs to be re-evaluated.

Cite

CITATION STYLE

APA

Khan, S. R., Manialawy, Y., & Siraki, A. G. (2019, December 1). Isoniazid and host immune system interactions: A proposal for a novel comprehensive mode of action. British Journal of Pharmacology. John Wiley and Sons Inc. https://doi.org/10.1111/bph.14867

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free